Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAMTGI)

Drug Name
SD-101 Drug Info
Synonyms HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 3 [1]
Skin disease EA00-EM0Z Phase 2 [2]
Melanoma 2C30 Phase 1/2 [3]
Squamous cell carcinoma 2B60-2D01 Phase 1/2 [3]
Squamous head and neck cell carcinom 2D60.0 Phase 1/2 [4]
Cross-matching ID
TTD Drug ID
DMAMTGI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Not Available [5]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatitis C virus infection
ICD Disease Classification 1E51.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 9 (TLR9) DTT TLR9 2.58E-01 -0.06 -0.17
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02521870) A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
5 Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.